RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY

RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY

Multiple myeloma (MM) usually responds to treatment but is incurable. The clinical course is characterised, in most patients, by a series of remissions and relapses. For younger patients, the initial treatment currently usually involves induction with the proteasome inhibitor bortezomib (BOR), alone...

Full description

Bibliographic Details
Main Authors:	María-Victoria Mateos, Enrique M. Ocio, Verónica González, Julio Dávila
Format:	Article
Language:	English
Published:	European Medical Journal 2015-07-01
Series:	European Medical Journal Hematology
Subjects:	multiple myeloma (mm) relapse proteasome inhibitor immunomodulator monoclonal antibody deacetylase inhibitor
Online Access:	https://emj.emg-health.com/wp-content/uploads/sites/2/2018/02/RelapsedRefractory-Multiple-Myeloma-The-Current-State-of-Play1.pdf

Similar Items

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
by: Parva Bhatt, et al.
Published: (2023-02-01)

Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
by: Danai Dima, et al.
Published: (2023-04-01)

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
by: Evangelos Terpos, et al.
Published: (2022-10-01)

Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
by: Arthur Bobin, et al.
Published: (2021-10-01)

Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis
by: Yongjin Zhi, et al.
Published: (2022-12-01)

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
by: Jiri Minarik, et al.
Published: (2022-10-01)

Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies
by: Margaret E. Stalker, et al.
Published: (2022-06-01)

Moving Toward Continuous Therapy in Multiple Myeloma
by: Francesca Bonello, et al.
Published: (2019-11-01)

A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study
by: Rafael Ríos-Tamayo, et al.
Published: (2023-12-01)

Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
by: Panagiotis Samaras, et al.
Published: (2019-04-01)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
by: Kazuhito Suzuki, et al.
Published: (2023-11-01)

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
by: Lorraine N. Davis, et al.
Published: (2021-04-01)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
by: Xavier Leleu, et al.
Published: (2023-02-01)

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
by: Luca Bertamini, et al.
Published: (2022-05-01)

Comorbidities in patients with multiple myeloma
by: L. P. Kuznetsova, et al.
Published: (2019-08-01)

Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
by: Marta Pelon, et al.
Published: (2024-03-01)

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
by: Kazuhito Suzuki, et al.
Published: (2021-09-01)

Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma
by: Francesca Alessandra Ambrosio, et al.
Published: (2023-02-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis
by: Xinyuan Gu, et al.
Published: (2023-12-01)

Therapeutic use of anti-sclerostin antibody in the treatment of multiple myeloma: A systematic review
by: Liza Ngomdir, et al.
Published: (2023-01-01)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
by: Angelica Ferro, et al.
Published: (2023-02-01)

Ixazomib in the treatment of relapsed multiple myeloma
by: S. V. Semochkin
Published: (2018-07-01)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
by: Elke De Bruyne, et al.
Published: (2013-04-01)

Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma
by: Li Zhang, et al.
Published: (2024-02-01)

The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review
by: Razwana Khanam, et al.
Published: (2023-05-01)

An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities
by: Maisa Siddiq Abduh
Published: (2024-02-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
by: Shigeki Ito
Published: (2020-01-01)

Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
by: Lu Ye, et al.
Published: (2023-12-01)

Presentation and Outcome of Patients with Multiple Myeloma (MM), Single Centre Experience from Windsor Essex Regional Cancer Centre
by: Kashash D, et al.
Published: (2024-02-01)

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

Roadmap for new practitioners to navigate the multiple myeloma landscape
by: Tiffany Tam, et al.
Published: (2022-09-01)

Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy
by: Maria Gkotzamanidou, et al.
Published: (2021-09-01)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
by: Sonia Morè, et al.
Published: (2020-11-01)

Multiple Myeloma Inhibitory Activity of Plant Natural Products
by: Karin Jöhrer, et al.
Published: (2021-05-01)

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
by: Irene Zamanillo, et al.
Published: (2023-08-01)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
by: Klaus Podar, et al.
Published: (2021-10-01)

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
by: Chen Wang, et al.
Published: (2020-07-01)

Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance
by: Philip Weir, et al.
Published: (2023-03-01)